QNTM
Quantum BioPharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.41
−2.43%Oct 6, 2026, 10:00 UTC
Quantum BioPharma signed a contract with Thermo Fisher Scientific's clinical research business to implement the Phase 2 Lucid-MS trial of its neuroprotective therapy in multiple sclerosis.
Source:Sep 24, 2026, 12:00 UTC
Unbuzzd Wellness, a licensee of Quantum BioPharma, appointed Zappy as its CEO.
Source:Sep 9, 2026, 12:30 UTC
Quantum BioPharma Ltd. received FDA clearance to begin clinical trials for a multiple sclerosis treatment.
Source:Aug 3, 2026, 17:50 UTC
Quantum BioPharma reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions.
Source:Jul 20, 2026, 23:00 UTC
Quantum BioPharma announced its intention to settle debt.
Jun 1, 2026, 23:30 UTC
Quantum BioPharma received FDA notification that its IND for Lucid-MS has been placed on clinical hold.